Religare Enterprises Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Religare Enterprises Limited FY26 consolidated revenue at ₹8,493.84 crore; Strategic initiatives to accelerate momentum in FY27".
RELIGARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Investment Company peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Religare Enterprises Limited reported FY26 consolidated revenue of ₹8,493.84 crore, up 14.7% from ₹7,405.47 crore in FY25. However, consolidated PAT declined significantly to ₹73.16 crore from ₹182.75 crore in the prior year. Q4 FY26 showed stronger revenue growth at 20.66% YoY to ₹2,473.3 crore, with PAT at ₹95.65 crore. Care Health Insurance posted gross written premium of ₹11,417 crore, up 24% YoY, gaining market share to 19.7% in the SAHI category. Religare Finvest became debt-free following RBI's removal of Corrective Action Plan restrictions. The company completed a ₹1,500 crore capital raise via convertible warrants to promoters and other investors, and the Board was substantially reconstituted with new leadership across all subsidiaries.
Revenue growth of 14.7% is positive, but the sharp decline in PAT from ₹182.75 crore to ₹73.16 crore is a concern for shareholders, indicating possible margin pressure or increased costs despite higher sales. The demerger of Financial Services business and leadership changes signal strategic restructuring that could create long-term value.